Advanced in Non-Alcoholic Fatty Liver Disease

Dr. Rohit Loomba

Hepatology
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
Advanced in Non-Alcoholic Fatty Liver Disease
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rohit Loomba is a Hepatologist in San Diego, California. Dr. Loomba is rated as an Advanced provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Visceromegaly, Cirrhosis, and Non-Alcoholic Fatty Liver Disease.

His clinical research consists of participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 12 clinical trials in the study of Non-Alcoholic Fatty Liver Disease.

Specialties
Hepatology
Licenses
Internal Medicine in MD
Hospital Affiliations
Uc San Diego Health Hillcrest - Hillcrest Med Ctr
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 W Arbor Dr, San Diego, CA 92103

Additional Areas of Focus

Dr. Loomba has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health
Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2026
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Vitamin E
Study Phase: Phase 2
Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study
Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Procedure
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Enrollment Status: Completed
Publish Date: August 13, 2025
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial.
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial.
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2025
Intervention Type: Biological
Study Drug: Lomecel-B medicinal signaling cells
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Enrollment Status: Completed
Publish Date: February 23, 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial
Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial
Enrollment Status: Completed
Publish Date: July 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

943 Total Publications

A Message From the Editors.
A Message From the Editors.
Journal: Alimentary pharmacology & therapeutics
Published: December 10, 2025
Similar Doctors
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Veeral Ajmera
Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Veeral Ajmera
Hepatology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 miles away)
858-249-6748
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Veeral Ajmera is a Hepatologist in San Diego, California. Dr. Ajmera is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Cirrhosis, Visceromegaly, Enlarged Liver, and Liver Transplant.

Elite in Non-Alcoholic Fatty Liver Disease
Dr. Tarek Hassanein
Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Tarek Hassanein
Hepatology

Southern California Liver Centers Inc

131 Orange Ave, Suite 101, 
Coronado, CA 
 (3.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tarek Hassanein is a Hepatologist in Coronado, California. Dr. Hassanein is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Hepatitis C, Hepatitis, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Liver Transplant.

Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Irine Vodkin
Hepatology
Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Irine Vodkin
Hepatology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 miles away)
858-657-7000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irine Vodkin is a Hepatologist in San Diego, California. Dr. Vodkin has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Cirrhosis, Alcoholic Cirrhosis, Visceromegaly, Liver Transplant, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Loomba's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile